Literature DB >> 6616970

C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.

A T Gewurz, S M Imherr, S Strauss, H Gewurz, C Mold.   

Abstract

Nephritic factor was detected in an individual whose serum showed a selective decrease in the third component of complement (C3) during and subsequent to an illness resembling disseminated gonococcal infection (DGI). As is characteristic of C3 nephritic factor (C3NeF), its activity was heat stable, was associated with IgG, and enhanced cleavage of normal human serum C3 via the alternative pathway. However, unlike previously reported cases of C3NeF detection in association with glomerulonephritis and/or lipodystrophy, this patient has had no significant disease before or more than 2 years after the apparent DGI. The significance of C3NeF in a healthy individual is unexplained, but this study suggests its occurrence may be more ubiquitous than previously suspected.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616970      PMCID: PMC1536206     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Identification of nephritic factor as an immunoglobulin.

Authors:  D G Williams; A Bartlett; P Duffus
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

2.  The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function.

Authors:  M R Daha; K F Austen; D T Fearon
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

3.  Disorders of the complement system in lipodystrophy.

Authors:  M M Ipp; J O Minta; E W Gelfand
Journal:  Clin Immunol Immunopathol       Date:  1977-03

4.  Heterogeneity of nephritic factor and its identification as an immunoglobulin.

Authors:  A E Davis; J B Ziegler; E W Gelfand; F S Rosen; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

5.  Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.

Authors:  M R Daha; L A van Es
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

6.  Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.

Authors:  A T Sobel; N R Cooper; R D Schreiber
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

7.  Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.

Authors:  L Halbwachs; M Leveillé; P Lesavre; S Wattel; J Leibowitch
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

8.  Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis.

Authors:  W M Bennett; E J Bardana; K Wuepper; D Houghton; W A Border; O Götze; R Schreiber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

9.  The complement abnormalities of lipodystrophy.

Authors:  J G Sissons; R J West; J Fallows; D G Williams; B J Boucher; N Amos; D K Peters
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

10.  Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis.

Authors:  D Lim; A Gewurz; T F Lint; M Ghaze; B Sepheri; H Gewurz
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

View more
  21 in total

1.  Requirements for the production of high-titre C3 nephritic factor (NEF) antibody in vitro.

Authors:  M A Marín; G Fontán; M López-Trascasa
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

Review 2.  Novel biomarkers in glomerular disease.

Authors:  Yasar Caliskan; Krzysztof Kiryluk
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

Review 3.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Authors:  Andrew S Bomback; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

4.  Molecular analysis of C3 allotypes in patients with nephritic factor.

Authors:  J E Finn; P W Mathieson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

Review 5.  Making sense of the spectrum of glomerular disease associated with complement dysregulation.

Authors:  Sally Ann Johnson; Edwin K S Wong; C Mark Taylor
Journal:  Pediatr Nephrol       Date:  2013-07-14       Impact factor: 3.714

6.  Causes of alternative pathway dysregulation in dense deposit disease.

Authors:  Yuzhou Zhang; Nicole C Meyer; Kai Wang; Carla Nishimura; Kathy Frees; Michael Jones; Louis M Katz; Sanjeev Sethi; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

7.  A healthy female with C3 hypocomplementemia and C3 Nephritic Factor.

Authors:  Maureen Egan; Kathleen Sullivan; Ashley Frazer-Abel; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2016-06-02       Impact factor: 3.969

Review 8.  Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.

Authors:  M C Pickering; H T Cook
Journal:  Clin Exp Immunol       Date:  2008-02       Impact factor: 4.330

Review 9.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 10.  The renaissance of complement therapeutics.

Authors:  Daniel Ricklin; Dimitrios C Mastellos; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.